- Home
- RCUS vs GNW Comparison
RCUS vs GNW Comparison
Compare RCUS & GNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCUS | GNW |
|---|---|---|
| Founded | 2015 | 1871 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | RCUS | GNW |
|---|---|---|
| Price | $25.23 | $9.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $39.91 | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 3.5M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.24 |
| Revenue | $247,000,000.00 | ★ $7,301,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $38.25 |
| Revenue Growth | N/A | ★ 0.08 |
| 52 Week Low | $13.21 | $7.84 |
| 52 Week High | $31.74 | $10.69 |
Technical Indicators
Market Signals| Indicator | RCUS | GNW |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 32.25 |
| Support Level | $25.94 | $9.09 |
| Resistance Level | $26.43 | $9.20 |
| Average True Range (ATR) | 1.07 | 0.26 |
| MACD | 0.10 | -0.12 |
| Stochastic Oscillator | 58.61 | 15.17 |
Price Performance
Historical ComparisonAbout RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
About GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has four main operating business segments: Enact, Closed Block segment, and Corporate and Other. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. The majority of the revenue is generated by the Enact segment. The company earns the maximum of its revenue in the United States.